HC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $16.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 389.30% from the company’s current price.

Separately, StockNews.com downgraded AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st.

AC Immune Price Performance

Shares of NASDAQ:ACIU opened at $3.27 on Wednesday. The firm has a fifty day simple moving average of $3.27 and a two-hundred day simple moving average of $3.45. AC Immune has a 52 week low of $2.25 and a 52 week high of $5.14.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.67). The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $91.60 million. On average, equities research analysts predict that AC Immune will post -0.89 EPS for the current year.

Institutional Trading of AC Immune

Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its position in AC Immune by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock valued at $2,602,000 after buying an additional 136,300 shares during the period. Assenagon Asset Management S.A. raised its position in AC Immune by 294.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after purchasing an additional 328,312 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of AC Immune by 315.6% in the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after buying an additional 8,423 shares during the period. Lazard Asset Management LLC bought a new position in shares of AC Immune during the 1st quarter worth $30,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of AC Immune by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after buying an additional 7,400 shares during the period. 51.36% of the stock is currently owned by institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.